Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-center, randomized, evaluator-blind trial of oral LFF571 in Clostridium difficile infection
2011-000947-26Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of LFF-571 in Clostridioides difficile colitis (CDI) (3 arms), sponsored by Novartis. Primary endpoint: Clinical response (clinical cure). Started May 2012; status: terminated.
02
Drugs
LFF-571
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2011-000947-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000947-26.